Larry the Cable Guy teams with Prilosec OTC on monster truck sweepstakes
CINCINNATI — Comedian Larry the Cable Guy has teamed up with Prilosec OTC to show racing fans that “You Can’t Beat Zero” by offering them great “Zero Experiences” at two top stock car races and a chance at winning Prilosec OTC’s hottest wheels: a “monster” utility vehicle.
“Racing is one of the best sports in America, and it’s best enjoyed with die-hard fans and tailgate food. When I’m out on the track all day I don’t let heartburn get in the way of a good time," Larry the Cable Guy stated. "That’s why I love Prilosec OTC. One pill a day gives me zero heartburn for a full 24 hours, and trust me, you can’t beat zero heartburn.”
Larry the Cable Guy will kick things off at the Daytona International Speedway on Feb. 23 from 9 a.m. to 1 p.m., followed by another race at the Texas Motor Speedway on April 6. At each stop, Larry will show fans why you can’t beat zero by hosting Prilosec OTC’s first ever “Zero Burn Games.” Game participants will be rewarded, and visitors will have the chance to fill up their tanks on “Zero Cost Concessions,” courtesy of Prilosec OTC.
Fans across the country will be able to keep up with Larry’s racing adventures by visiting FoxSports.com/PrilosecOTC to watch video highlights. Fans will also have the opportunity to win the ultimate tailgate accessory — a “monster” utility vehicle — and set off on an ultimate zero experience of their own by entering the You Can’t Beat Zero Sweepstakes.
From Feb. 20 until May 30, participants can enter at YouCantBeatZero.com for a chance to win the vehicle and a trip for two to a stock car race of their choice courtesy of Prilosec OTC. One winner will be chosen at random to receive the prize pack, which includes two tickets to a 2014 stock car race, a “monster” utility vehicle, travel and accommodations (a two-night hotel stay and air transportation for each destination), and one $1,000 gift card.
West Virginia prescription-only PSE bill passes Senate, heads to House of Delegates
CHARLESTON, W.Va. — The West Virginia Senate on Tuesday voted 25-to-9 to make pseudoephedrine a Schedule IV prescription drug and exempt medicines that can’t easily be diverted to methamphetamine, according to published reports. A similar bill is being considered by the West Virginia House of Delegates.
According to reports, the two exceptions to the prescription-only requirement would include Acura Pharmaceuticals’ Nexafed and Westport Pharmaceuticals’ Zephrex-D.
"It is very disheartening that certain members of the West Virginia legislature are determined to impose higher healthcare costs and onerous burdens on responsible taxpayers in the face of overwhelming evidence that such an approach would fail to address the root causes of the methamphetamine problem," said Carlos Gutierrez, senior director and head of state government affairs for the Consumer Healthcare Products Association.
"Under a prescription requirement, thousands of West Virginians will have to take time off from work or school, drive to the doctor and pay additional copays at the pharmacy — just to get the nonprescription medicines they rely on to treat common cold and seasonal allergy symptoms. It would be one thing if the costs of these considerable burdens led to significant gains against meth cooks and dealers, but any honest examination of other states that have passed such a policy reveals that meth-related crime remains a vexing problems for law enforcement officials in those states," he said. "We would also urge members of the House of Delegates to consider the fact that West Virginia’s greatest drug threat involves narcotics that already require a prescription."
ERSP recommends truDERMA discontinue certain claims supporting Troxyphen
NEW YORK — The Electronic Retailing Self-Regulation Program on Tuesday recommended that truDERMA discontinue certain claims for the company’s Troxyphen dietary supplement, including claims that the product is “safe and clinically researched.”
As support for the performance and establishment claims at issue, the marketer submitted testing on its key ingredient. After reviewing the evidence, ERSP concluded that truDERMA provided a reasonable basis for claims relating to an “increased sex drive.”
However, ERSP determined that the marketer did not provide adequate support for claims that Troxyphen will “burn excess fat” or that users will “gain muscle mass.” ERSP recommended that the marketer discontinue any claims of weight and/or fat loss, increased muscle and improved BMI.
ERSP also recommended that the marketer discontinue claims that promise quantified performance results and modify general claims of increased testosterone by disclosing that the product must be used in conjunction with resistance training.
The marketer did not provide evidence indicating that the dosages of ingredients contained in Troxyphen will provide the results specifically stated in the advertising. As a result, ERSP recommended truDERMA discontinue several ingredient claims and the claim that “Troxyphen is safe & clinically researched.”
The company, in its marketer’s statement, said, “truDERMA appreciates ESRC’s comments and direction on our advertising. We are committed to helping people lead healthier, happier lives. truDERMA will give serious consideration to ESRC’s recommendations in our advertising practices.”
ERSP is an investigative unit of the advertising industry’s system of self-regulation and is administered by the Council of Better Business Bureaus. The marketer’s advertising came to the attention of ERSP through an anonymous competitive challenge.